<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Urologija - Invento Health Care Group</title>
	<atom:link href="https://eng.inventohcg.com/project-category/urologija/feed/" rel="self" type="application/rss+xml" />
	<link>https://eng.inventohcg.com</link>
	<description>Birčaninova 2/42 Savski venac, Beograd</description>
	<lastBuildDate>Thu, 07 Mar 2024 07:33:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.2</generator>
	<item>
		<title>Seratrix</title>
		<link>https://eng.inventohcg.com/proizvodi/seratrix/</link>
					<comments>https://eng.inventohcg.com/proizvodi/seratrix/#respond</comments>
		
		<dc:creator><![CDATA[eoranges]]></dc:creator>
		<pubDate>Sun, 07 Mar 2021 07:26:55 +0000</pubDate>
				<guid isPermaLink="false">https://eng.inventohcg.com/?post_type=dt_portfolio&#038;p=550</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[<div class="vc_row wpb_row vc_row-fluid"><div class="wpb_column vc_column_container vc_col-sm-2/5"><div class="vc_column-inner"><div class="wpb_wrapper">
	<div  class="wpb_single_image wpb_content_element vc_align_center">
		
		<figure class="wpb_wrapper vc_figure">
			<div class="vc_single_image-wrapper   vc_box_border_grey"><img fetchpriority="high" decoding="async" width="720" height="600" src="https://eng.inventohcg.com/wp-content/uploads/2024/03/seratrix.jpg" class="vc_single_image-img attachment-full" alt="" srcset="https://eng.inventohcg.com/wp-content/uploads/2024/03/seratrix.jpg 720w, https://eng.inventohcg.com/wp-content/uploads/2024/03/seratrix-300x250.jpg 300w" sizes="(max-width: 720px) 100vw, 720px"  data-dt-location="https://eng.inventohcg.com/seratrix-2/" /></div>
		</figure>
	</div>
</div></div></div><div class="wpb_column vc_column_container vc_col-sm-3/5"><div class="vc_column-inner"><div class="wpb_wrapper">
	<div class="wpb_text_column wpb_content_element  vc_custom_1672824960803" >
		<div class="wpb_wrapper">
			<h6>STRONG, STRONGER, THE STRONGEST&#8230;</h6>
<h1>SERATRIX®</h1>
<h4>Gastro-resistant capsules</h4>

		</div>
	</div>

	<div class="wpb_text_column wpb_content_element  vc_custom_1696849607544" >
		<div class="wpb_wrapper">
			<p>Combination of proteolytic enzymes<br />
<strong>Serapeptase 250,000 SPU Trypsin 335,000 IU Chymotrypsin 65,000 IU</strong></p>
<p>SERATIOPEPTIDASE DECOMPOSES TOXINS AND PROTEIN REMAINS ASSOCIATED WITH INFLAMMATION, INCLUDING THE ABILITY TO BREAKDOWN NON-LIVING TISSUE, DOES NOT USE HEALTHY CELLS AS A SUBSTRATE.</p>
<p><strong>• ANTI-INFLAMMATORY EFFECT</strong> The anti-inflammatory activity of seratiopeptidase is attributed to the hydrolysis of inflammatory mediators such as bradykinin, histamine and serotonin. Proteolytic activity on the cell surface leads to changes in the adhesion of molecules that direct inflammatory cells to their targets.<br />
<strong>• ANTI-EDEMATOUS EFFECT</strong> Dilutes fluid caused by inflammation and injury, allowing it to be eliminated faster, dissolves dead tissue around the wound, improves microcirculation at the site of injury and leads to an acceleration of the repair process of damaged tissue.<br />
<strong>• FIBRINOLYTIC EFFECT</strong> Breaks down fibrin, an insoluble protein by-product of blood coagulation.<br />
<strong>• ANALGESIC EFFECT</strong> Relieves pain by preventing the release of pain-causing amines, such as bradykinin. It hydrolyzes inflammatory mediators, which reduces swelling and improves microcirculation, thereby reducing pain caused by pressure on nerve endings at the site of inflammation.<br />
<strong>• EFFECT ON BIOFILM</strong> Serratiopeptidase exhibits the property of modifying adhesion molecules and thus reduces proteins on the cell surface. Serratiopeptidase modulates adhesion expression in some bacterial species and enhances the efficacy of AB against Biofilm-forming bacteria.</p>
<p>CHYMOTRYPSIN, A PROTEOLYTIC ENZYME, CUTS PROTEINS AT PLACES ALONG THE PROTEIN CHAIN THAT CONTAIN VERY LARGE AMINO ACIDS SUCH AS PHENYLALANNINE, TYROSINE AND TRYPTOPHANE.</p>
<p>It helps reduce redness and swelling caused by surgery or infection and helps heal wounds/traumatic tissue injuries faster. Its anti-inflammatory, antioxidant and anti-infective properties help to resolve the inflammation caused by the injury and help to facilitate the healing process. Trypsin and chymotrypsin are proteolytic enzymes that remove swelling by exerting a proteolytic effect on wounds, hematoma and pain, promote phagocytosis to remove cellular debris and accelerates recovery. They help relieve severe pain and swelling in postoperative wounds and other inflammatory diseases.</p>
<p>TRYPSIN IS ONE OF THE MOST IMPORTANT EXOGENOUS PROTEIN HYDROLASES AND CAME INTO CLINICAL USE IN THE 1960&#8217;S. TRYPSIN IS AN ENDOPEPTIDASE THAT SELECTIVELY HYDROLYZES PEPTIDE CHAINS ON ARGININE AND LYSINE RESIDUES, WHICH ARE CREATED IN AN INFLAMMATORY RESPONSE. EXOGENEOUSLY INJECTED TRIPSIN ACCELERATES WOUND HEALING BY WEAKENING THE INFLAMMATORY REACTION, REDUCING EDEMA AND PROTECTING AGAINST INFECTION.</p>
<p>Reduces the effects of pro-inflammatory cytokines such as IL-1, TNF-a and IFN-g in tissues under inflammation Restarts the fibrinolytic process in inflamed and injured tissues, the fibrin barrier is broken, promoting the absorption of fibrin exudate Helps restore local microcirculation, remove inflammatory edema and promoting tissue regeneration. Trypsin also acts on macrophages. Exogenous application of trypsin may therefore have anti-infective properties, by inducing enhanced phagocytic activity of macrophages, thereby enhancing phagocytosis at the site of infectious inflammation. Trypsin plays a role in promoting wound healing by regulating fibroblast differentiation.</p>
<p><strong>SERATRIX®</strong> is widely used in many fields of medicine:</p>
<ul>
<li><strong>Orthopedics:</strong> traumatic swelling after sports injuries, fractures, sprains, lacerations, osteoarticular infection at the site of AB application, reduction of joint edema and soft tissue damage and improvement of postoperative recovery speed.</li>
<li><strong>Surgery:</strong> traumatic and postoperative inflammation, treatment of active inflammatory edema associated with post-surgical wounds, treatment of traumatic hematomas, ulcers and fistulas, venous inflammatory disease</li>
<li><strong>Gynecology:</strong> fibrocystic breast diseases, hysterectomy, PID, episiotomy, caesarean section.</li>
<li><strong>Pulmonology:</strong> bronchitis, inadequate expectoration of sputum in bronchial asthma, after anesthesia</li>
<li><strong>Urology:</strong> postoperative inflammation, BHP, cystitis, epididymitis</li>
<li><strong>ENT:</strong> sinusitis, rhinitis, laryngitis, tonsillitis</li>
<li><strong>Rheumatology:</strong> rheumatoid arthritis, osteoarthritis</li>
<li><strong>Dentistry:</strong> anti-inflammatory after interventions, surgery, periodontitis, to increase the concentration of antibiotics at the site of infection</li>
</ul>
<p>Gastro-resistant capsules &#8211; without dissolution and loss of activity in an acidic environment</p>
<p><strong>Dosage</strong> &#8211; 1 capsule once a day, for adults only.</p>
<p><strong>Warnings</strong> &#8211; do not use two weeks before surgery. Consultation with a doctor and pharmacist for people with ulcers, GI lesions and on anticoagulant therapy</p>
<p><strong>Effect:</strong> Anti-inflammatory, anti-edematous, analgesic, mucolytic, fibrinolytic, effect on biofilm</p>
<p><em>*Teller, P.; White, T.K. The Physiology of Wound Healing: Injury Through Maturation. Perioper. Nurs. Clin. 2011, 6, 159–170</em><br />
<em>**Strodtbeck, F. Physiology of wound healing. Newborn Infant Nurs. Rev. 2001, 1, 43–52.</em><br />
<em>***Hogan, S.; Zapotoczna, M.; Stevens, N.; Humphreys, H.; O’Gara, J.; O’Neill, E. Potential use of targeted enzymatic agents in the treatment of Staphylococcus aureus biofilm-related infections. J. Hosp. Infect. 2017, 96, 177–182.</em><br />
<em>****Mecikoglu, M.; Saygi, B.; Yildirim, Y.; Karadag-Saygi, E.; Ramadan, S.S.; Esemenli, T. The effect of proteolytic enzyme serratiopep-tidase in the treatment of experimental implant-related infection. JBJS. 2006, 88, 1208–1214.</em><br />
<em>****Selan, L.; Papa, R.; Tilotta, M.; Vrenna, G.; Carpentieri, A.; Amoresano, A.; Pucci, P.; Artini, M. Serratiopeptidase: A well-known metallo-protease with a new non-proteolytic activity against S. aureus biofilm. BMC Microbiol. 2015, 15, 207.</em></p>
<p><strong>Registration number:</strong> 515-02-01885-23-003 from August 25, 2023</p>
<p><a href="https://www.inventohcg.com/wp-content/uploads/2024/03/seratrix.pdf" target="_blank" rel="noopener">More informations</a></p>

		</div>
	</div>
</div></div></div></div><p>The post <a href="https://eng.inventohcg.com/proizvodi/seratrix/">Seratrix</a> first appeared on <a href="https://eng.inventohcg.com">Invento Health Care Group</a>.</p>]]></content:encoded>
					
					<wfw:commentRss>https://eng.inventohcg.com/proizvodi/seratrix/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
